Ezra GLP-1 Reviews: Identity, Terms, and FDA Record

Resolve the Ezra identity before reading reviews

A current direct capture of `joinezra.com` returned a 404 page. A separate current page served from `go.joinezra.com/policy/terms-of-service` displayed Mondae terms, named Mondae LLC, and carried a revision date of December 11, 2024. Current Mondae terms also name Mondae LLC. [S8][S7][S1]

The FDA warning letter is addressed to “Ezra Holdco LLC dba Ezra.” It gives a June 8, 2026 date and the Sheridan, Wyoming address also printed for Mondae LLC in current Mondae terms. That shared address is observable evidence, but the captured pages do not state the legal relationship between the two companies. Merger, rename, successor status, liability transfer, and customer-account continuity are all **Not stated**. [S5][S1]

This guide concerns only the GLP-1 service surfaces found for the exact query.

Build a dated identity timeline.

Identity questions become easier to audit when each observation keeps its own date and source. The current root capture shows `joinezra.com` returning a 404 page. A current capture from the legacy `go.joinezra.com` subdomain serves Mondae-branded terms carrying a December 11, 2024 revision date. The current `mondae.com` terms name Mondae LLC and describe that company’s website and services. Those are three separate observations, not one proof of a legal transition. [S8][S7][S1] The captured current `mondae.com` terms page did not state an effective or last-updated date; it was checked August 27, 2026. The December 11, 2024 revision date applies only to the captured `go.joinezra.com` terms page. [S1][S7]

Record them as a timeline: domain observed, page title, named entity, stated revision date when available, capture date, and unanswered relationship fields. This prevents a later reader from turning page sequence into an unsupported merger or successor conclusion. It also makes an old review easier to place. A post can be labeled by the public domain, terms revision, and service surface visible when the author wrote it, without assuming the current checkout has the same roles or contract.

The FDA record belongs on that timeline as a separate regulator event. It names Ezra Holdco LLC dba Ezra, gives the letter date, and identifies the website FDA reviewed in May 2026. Current Mondae terms name a different legal entity. The captured sources allow both facts to be recorded, but they do not supply the legal bridge between them. [S5][S1]

When a review uses only “Ezra,” ask four questions before applying it to a current decision: Which domain did the author use? Which legal entity appeared in the saved terms or receipt? Which clinical and pharmacy roles were named? Which date anchors the experience? If those fields are missing, the review may still describe that author’s report, but it cannot close the current identity gap.

What the current Mondae surface says

Mondae’s homepage currently presents compounded semaglutide and compounded tirzepatide. It describes a questionnaire, a required consultation with a licensed care provider, and shipment only if a medication is prescribed. The same page calls Mondae a telehealth platform that connects eligible patients with licensed providers and says a licensed pharmacy dispenses and ships when prescribed. [S2]

Current terms separate those roles further. They describe access to provider and pharmacy services, say health records, appointments, communications, and pharmacy services may be provided by third-party unaffiliated providers, and identify Mondae as a technology platform rather than a medical provider. The terms state that telehealth services are provided through Bask Telehealth LLC. [S1]

That role separation matters more than a brand-level review. A reader still needs the clinician authorized for the patient’s location, the exact dispensing pharmacy, and the compounder that produced any compounded product. Those identities are **Not stated for an individual transaction** in the captured public pages. The provider, product, and pharmacy can vary, so verify the exact transaction rather than carrying forward an old reviewer’s details. [S1][S2]

The current terms say services are for people located in the United States and condition eligibility on being in a state where Mondae operates, depending on the type of service. They also say satisfying requirements does not guarantee services. The homepage separately says Mondae is available in all 50 states. Read these statements by scope: broad platform or delivery availability does not prove that every product, clinician, or service is available to every reader in every state. [S1][S2]

Use the current program and product-status guide to verify the exact offer; this article stays with identity and terms.

Separate the platform, clinician, pharmacy, and compounder.

The public service page describes a questionnaire, provider review, and shipment by a licensed pharmacy if prescribed. The current terms describe access to independent provider and pharmacy services, identify Mondae as a technology platform rather than a medical provider, and name Bask Telehealth LLC for telehealth services. These descriptions establish advertised role categories, but they do not name the clinician, dispensing pharmacy, or compounder assigned to an individual transaction. [S2][S1]

Build one evidence row for each role instead of writing “Ezra” or “Mondae” across the whole transaction. For the platform, save the terms entity and support route. For clinical service, save the practice and clinician information presented to the patient. For dispensing, save the pharmacy name and official license record. For a compounded product, separately record the producer identified on the product label or transaction documents.

This separation directly answers a limitation FDA highlights in its general compounding Q&A: people purchasing compounded drugs online may not know the identity of the compounder. The same Q&A distinguishes state-board oversight of ordinary state-licensed pharmacies from FDA oversight of registered outsourcing facilities. A platform name alone therefore cannot answer which entity produced or dispensed a particular item. [S6]

Do not fill a missing role from another customer’s review. Their clinician, pharmacy, product, location, or checkout may differ. Leave each field unresolved until the current transaction or an official record supplies it, then verify a named pharmacy through the online GLP-1 pharmacy guide.

Read price and subscription language together

The captured pages do not support one durable “Ezra price.” Current Mondae terms say prices may change and authorize charges described during a transaction, including recurring fees for subscription services. They say a cancellation cutoff and cancellation instructions are presented when a subscription is purchased. [S1]

The semaglutide product page says “No membership fees,” while another section says the starting rate remains the same while a membership remains active. The shipping policy says an order may be a one-time shipment or a subscription, depending on checkout. These statements may refer to different offers or charge labels; the captured pages do not reconcile them. Treat the exact checkout configuration as controlling evidence to save, not as an invitation to invent one universal fee model. [S9][S3]

Current terms describe cash payment and say Mondae and providers do not accept commercial insurance, are not in-network with commercial plans, and are not enrolled with federal or state health programs. “Insurance not required” on the service page is therefore not the same as insurance coverage. [S1][S9]

Before authorizing payment, copy the itemized first charge, consultation fee, medication charge, shipping amount, recurring interval, cancellation cutoff, and refund rule. If insurance support is part of another comparison, keep administrative support separate from plan coverage using the insurance support versus coverage guide.

Preserve the checkout as transaction evidence.

The current terms authorize charges presented during a transaction, including recurring fees associated with subscription services, and say subscription cancellation details are presented when a subscription is purchased. The shipping policy allows either a one-time shipment or a subscription depending on the checkout choice. Together, those sources make the saved checkout more useful than a single advertised amount. [S1][S3]

Capture the product description, quantity or interval shown, first payment, later payment, renewal trigger, shipping line, consultation line, cancellation method, and cutoff. Save the timestamp and the terms and refund links displayed beside authorization. If a field is absent, write “Not stated” rather than assuming it is included in the visible total.

Keep conflicts visible in the record. The product page uses both “No membership fees” and active-membership wording, while the refund policy says consultation fees are nonrefundable, including when medication is not prescribed. The homepage separately describes charge timing tied to physician approval. These statements should be taken back to the current checkout and written support; they should not be compressed into a universal fee or refund promise. [S9][S4][S2]

After purchase, compare the receipt with the saved checkout using the same field names. That produces a reviewable transaction record without claiming that another reader will see the same offer. Repeat the comparison before renewal because the terms state that prices may change. [S1]

Shipping, cancellation, and refunds

Mondae’s shipping policy says standard shipping is included, an approved prescription typically ships express within five to seven days after approval, and tracking is sent by email. It also describes insulated temperature-controlled packaging for certain compounded medications and directs customers to support for delayed, damaged, lost, or stolen shipments. These are publisher terms, not a fulfillment guarantee. [S3]

The refund policy narrows cancellation. It says medication cannot be returned after dispense or shipment, cancellation is available only before dispense or shipment, and refund requests are reviewed only in limited situations. It requires damaged or defective issues to be reported within 48 hours and says consultation fees are nonrefundable, including when no medication is prescribed. [S4]

That last term deserves comparison with the homepage statement that a customer will not be charged until a physician approves treatment. The captured pages do not explain whether a separate consultation fee can apply before that event, whether the statements govern different offers, or which event counts as approval. The answer is **Not stated**. Ask for the exact payment event and fee treatment in writing before checkout. [S2][S4]

What the FDA warning letter establishes

FDA’s June 8, 2026 warning letter says its May 2026 website review identified violations involving Ezra’s presentation of compounded semaglutide and tirzepatide. Specifically, FDA said pictured labels identified “Ezra,” suggesting Ezra was the compounder when it was not. The letter characterized the representations as false or misleading under the cited provisions. [S5]

The letter requested a written response within 15 business days and described possible corrective information, including identifying entities that produce offered compounded products and addressing website claims. It also says the letter notifies the recipient of FDA’s concerns and provides an opportunity to address them. [S5]

The captured official page does **not** state a current response, correction, closeout, or final disposition. It would be inaccurate to say the warning was resolved, and equally inaccurate to claim the capture proves a final adjudication. Record the letter, date, addressee, stated findings, and procedural limit exactly. [S5]

FDA’s general compounding Q&A says compounded drugs are not FDA-approved and FDA does not verify their safety, effectiveness, or quality before marketing. It also encourages research into online pharmacies and notes that customers buying compounded drugs online may not know the compounder’s identity. Those general boundaries explain why the pharmacy and compounder fields matter; they do not determine an individual’s care or declare every compounded product unlawful. [S6]

Keep regulator record, product status, and current disposition separate.

Use three distinct fields for the regulator material. First, the warning-letter record: addressee, date, reference number, website reviewed, stated findings, and requested response. Second, the general product-status boundary from FDA’s compounding Q&A. Third, current disposition. The captured official warning-letter page supports the first field, and the Q&A supports the second; the current disposition remains Not stated. [S5][S6]

A response request does not prove closeout; absent closeout language does not prove no response or correction.

Apply the same separation when reviewing current marketing. Compare the exact product description and named compounder against the current transaction documents. Do not use an old pictured label, a platform name, or a customer post to decide current product identity. FDA’s letter specifically focused on how pictured labels represented the compounder, which makes exact label and producer records decision-bearing rather than incidental. [S5]

Use the current online GLP-1 pharmacy verification guide to check a named dispensing pharmacy through official sources. Keep that check separate from judging the platform brand.

Why this is not a customer-score review

The exact results placed Trustpilot and Reddit pages near the top, but their bodies were not accessible in the current direct Firecrawl captures. No current numerical rating, review count, complaint theme, delivery theme, or customer consensus can be verified from those pages in this packet. Search snippets are discovery evidence, not a substitute for the review body. [S11]

Even when a customer post is accessible, it establishes only reported experience. It cannot verify the current legal entity, controlling terms, assigned clinician, pharmacy license, product identity, or another customer’s outcome. Dates matter: an Ezra-era post may concern a different public surface or terms revision than the current Mondae checkout.

A useful review verdict is therefore conditional. Current first-party evidence shows an active Mondae GLP-1 service surface and detailed terms, shipping, and refund pages. It also leaves legal continuity and transaction-specific roles unstated, contains statements that require checkout reconciliation, and sits beside a material FDA warning-letter record. That is enough for a due-diligence conclusion, not a good-or-bad customer consensus. [S2][S1][S3][S4][S5][S9]

Match each review statement to the question it can answer.

For an old Ezra review, record only its date, domain, named roles, charge labels, shipment or support event, and reported result. Mark changed or missing current fields as Not stated.

This method also protects against snippet overreach. The dated feature-specific Firecrawl attempts did not expose featured-snippet, People Also Ask, image-pack, video-pack, or comparable-price module content. The FAQ below is therefore built from the direct source and failed-closed feature records, not copied from an unobserved search feature. [S10]

Prepayment record and update policy

Create a dated one-page record before paying:

Sources and terms were checked August 27, 2026. Recheck before payment, refill, or renewal, and whenever a brand, domain, legal entity, provider, pharmacy, product, price, shipping method, or policy changes. If a material field remains unstated, leave it unresolved. Do not fill it from an old review. [S11]

1. Save the current service page, terms, shipping policy, refund policy, and checkout.
2. Record the legal terms entity and keep “Ezra versus Mondae relationship: Not stated” unless a controlling source answers it.
3. Ask for the clinical-practice name, clinician pathway, dispensing pharmacy, and compounder identity.
4. Copy the exact product description and distinguish compounded from FDA-approved product status.
5. Itemize consultation, medication, shipping, subscription, renewal, cancellation, and refund terms.
6. Preserve any conflict and the written response that resolves it.
7. Recheck the FDA page for later public correspondence or closeout information without assuming silence proves status.